Somewhere in a hospital trust research office, a protocol for a first-in-human study sits in an inbox awaiting a regulator’s verdict. The sponsor, a small company with a limited runway, is counting weeks. Each one costs money, and some cost the study its place in the UK altogether. Under the strategy published by the MHRA, that wait for qualifying Phase 1 trials is to fall to 14 days, with fees linked to guarantees and rebates owed when the agency misses them.

That commitment deserves attention well beyond the life sciences sector. The UK has spent a decade telling itself it can be a leading place to develop medicines while watching slow approvals and uncertain timelines push investment elsewhere. A regulator that publishes service guarantees, accepts financial consequences for missing them and reinvests fee income in expertise is addressing the problem where it sits. Ninety days for a first assessment of a licensing application, and the same for scientific opinions, gives companies a figure to plan around. Investors have asked for exactly that.

The relevance to the NHS is direct and runs through its finances. The strategy commits to faster decisions on generics and biosimilars so that savings reach the health service as early as possible. For trusts and integrated care boards managing tight budgets, earlier biosimilar entry is a practical lever on drug spend. The joint pathway with NICE, which the agency says could bring some medicines to patients three to six months earlier, answers a longstanding frustration. Licensing and value assessment have run in sequence for too long, and parallel decisions shorten the interval in which a treatment exists but cannot be prescribed.

Health data is the second major strand. The MHRA plans to improve access to real-world data from hospitals and genomics, and to work with the Health Data Research Service on real-time surveillance. The NHS holds one of the richest longitudinal datasets in the world, and its value has been discussed more readily than realised. A regulator that wants to use that data to detect safety signals earlier gives it a clear and publicly beneficial purpose. Simpler Yellow Card reporting should widen the flow of information, and clinicians who report an adverse event will see the effort return as faster safety action.

The agency’s approach to artificial intelligence merits a measured welcome. Using AI for application triage and evidence pre-screening applies the technology to a defined internal process, and the planned protocol checker lets sponsors identify common grounds for rejection before they submit. A new Centre for AI and Digital Health and a framework for AI as a medical device follow. NHS leaders under pressure to adopt digital tools have often lacked clear regulatory expectations to procure against. Clarity from the regulator lowers the risk that a trust buys a product whose status is later questioned.

Political timing sharpens the case. Ministers have tied the strategy to economic growth and a stronger NHS, two aims that rarely align so neatly in one policy instrument. A faster regulator supports inward investment and, through earlier access and cheaper generics, supports the health service’s own budget. Patients stand to gain from the commitments on diversity in clinical studies, a Women’s Health Plan this year and a refreshed patient involvement plan, which address long-recorded gaps in who is studied and who is heard.

A credible reading includes the risks. Guarantees only matter if capacity follows, and the agency will recruit specialists in competition with industry. The rare disease framework still has no publication date following consultation. Higher fees will test the goodwill of the companies asked to pay them. Yet the design of the strategy anticipates this scrutiny, since rebates make failure visible and costly to the regulator itself. That is a rare feature in public administration.

For NHS leaders, the task now sits on the demand side. Faster licensing and earlier NICE decisions will bring new medicines to commissioners and service planners sooner than current workforce plans and pathways may assume. The MHRA has offered a clock. The rest of the system should prepare to keep time with it.

‍